Marker Therapeutics Inc (MRKR)

[Burrhead1]

I just received this response.......nothing different:

I can tell you there is a lot of concern that maybe the company is not being forthright with their investors. We should have had interim results by now on this trial and the final results of the Phase 1 trial in a distinguished journal.......everything seems to be very late! Below is what was said during the 3rd Quarter earnings report:

Data from the first 27 patients enrolled in the study are currently being analyzed by the study's clinical investigators at MSKCC. TapImmune anticipates reporting the results based on these 27 patients in the first half of 2018. If the safety profile remains favorable and there are sufficient signs of tumor response, patient enrollment may resume and the study can be completed as designed.


Hi Dave, sorry for no response last week. I must have not seen the notification. We are working on the interim analysis for the MSKCC study. When dealing with third parties, it can be difficult to get things out on time. Once we hear back about the interim analysis we will be sure to put the word out.

I’m disappointed that I received no response to my message sent last week.......is there any way our CEO can at least tell us about when we might receive some interim results?